CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Poolbeg Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Poolbeg Pharma PLC
42 New Road
Phone: +44 2071831499p:+44 2071831499 LONDON, E1 2AX  United Kingdom Ticker: POLBPOLB
Business Summary
Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Cathal M.Friel 61 2/15/2024 3/19/2021
Chief Executive Officer, Executive Director JeremySkillington 52 7/19/2021 7/19/2021
Chief Financial Officer, Executive Director IanOconnell 35 5/20/2021 5/20/2021
6 additional Officers and Directors records available in full report.

Business Names
Business Name
POLB
POLBF

General Information
Number of Employees: 10 (As of 12/31/2024)
Outstanding Shares: 697,200,000 (As of 6/25/2025)
Stock Exchange: LON


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 25, 2025